A year to forget for medtech stocks
The biggest surprise is that there were a handful of risers despite the widespread market turmoil.
Few big bangs in a quiet year for medtech mergers
J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.
Boston’s struggle with obesity
With an effective obesity drug already available and more in the pipeline, what hope do devices have?
Big medtechs’ efficiency starts to recover from Covid
Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.
Medtech bleeds corporate venture cash
Overall venture investment in the sector remains steady, but the big strategics back off.
Medtech takes on pain
Attempts to treat pain with non-opioid drugs have ended in repeated failures – but device makers have met with greater success.
The other shoe finally drops for device dealmaking
A combination of Covid and market gloom results in the fewest acquisitions closing for over 20 years.
